Abstract
Primary neuroendocrine tumors of the urinary bladder are relatively rare and are comprised of a heterogeneous group of neoplasms. These include well-differentiated neuroendocrine tumors (WDNETs) or carcinoid tumors; poorly differentiated neuroendocrine carcinomas (NEC), including small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC); and paraganglioma. These tumors are believed to arise from native neuroendocrine cells in the urothelial lining in the case of WDNETs, transdifferentiation of urothelial carcinoma cells in the case of poorly differentiated NECs, and chromaffin cells in autonomic ganglia in the case of paraganglioma. These tumors have different treatment protocols and clinical outcomes than conventional urothelial carcinoma, with SCNEC and LCNEC having a more aggressive course and worse outcomes and WDNET and paraganglioma having a more indolent course and better outcomes. Therefore, the proper recognition of these tumors is important. The epidemiological data; clinical information; histopathologic, immunohistochemical, and molecular features; prognostic factors; and therapeutic approaches of these entities are discussed in this chapter.
Original language | English (US) |
---|---|
Title of host publication | Urinary Bladder Pathology |
Publisher | Springer International Publishing |
Pages | 113-128 |
Number of pages | 16 |
ISBN (Electronic) | 9783030715090 |
ISBN (Print) | 9783030715083 |
DOIs | |
State | Published - Jun 1 2021 |
Keywords
- Carcinoid tumor
- Immunohistochemical features
- Large cell neuroendocrine carcinoma
- Molecular changes
- Neuroendocrine carcinoma
- Neuroendocrine tumors
- Paraganglioma
- Small cell neuroendocrine carcinoma
- Urinary bladder
- Well-differentiated neuroendocrine tumor
ASJC Scopus subject areas
- Medicine(all)